+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dengue Testing Market by Test Type, Technology, End User, Product Type, Setting, Sample Type - Global Forecast to 2030- Product Image
Dengue Testing Market by Test Type, Technology, End User, Product Type, Setting, Sample Type - Global Forecast to 2030- Product Image
Sale

Dengue Testing Market by Test Type, Technology, End User, Product Type, Setting, Sample Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083753
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dengue Testing Market grew from USD 527.02 million in 2024 to USD 558.61 million in 2025. It is expected to continue growing at a CAGR of 5.77%, reaching USD 738.13 million by 2030.

Redefining Dengue Diagnostics for Modern Healthcare

Dengue fever continues to exert significant pressure on global health systems, particularly in tropical and subtropical regions where transmission is endemic. Recent surges in reported cases have underscored the critical importance of accurate and timely diagnostic testing as a cornerstone of effective disease management. Rapid identification of dengue infection not only facilitates prompt clinical intervention but also supports robust epidemiological surveillance, guiding public health responses and outbreak containment strategies.

In this complex environment, diagnostic stakeholders must navigate a labyrinth of test formats, evolving technologies, and regulatory requirements. From antibody-based assays that reveal past exposure to molecular methods that detect active viral replication, each testing modality delivers distinct clinical and operational benefits. Meanwhile, health systems strive to optimize resource allocation, balancing the need for high-throughput laboratory solutions with the growing demand for point-of-care diagnostics in decentralized settings.

This executive summary distills the latest trends, market dynamics, and strategic imperatives shaping the dengue testing ecosystem. By examining transformative shifts, tariff impacts, segmentation drivers, regional nuances, competitive landscapes, and actionable recommendations, this report offers a comprehensive framework to inform decision-making across the value chain. Whether you are a product innovator, a diagnostic laboratory director, or a healthcare policy architect, the insights herein will equip you to anticipate challenges, seize opportunities, and chart a course toward more resilient and responsive dengue testing solutions.

Emerging Shifts Shaping the Dengue Testing Ecosystem

The dengue testing landscape is undergoing profound transformation, driven by advances in assay design, digital integration, and shifting care delivery models. Point-of-care testing, once limited by sensitivity concerns, has matured through innovations in lateral flow immunoassays and fluorescence detection, enabling reliable results outside centralized laboratories. At the same time, laboratory workflows are being reimagined with automated platforms that leverage microarray technology and real-time polymerase chain reaction to deliver higher throughput and enhanced multiplexing capabilities.

Regulatory bodies across key markets have introduced accelerated pathways for novel diagnostic modalities, reflecting growing recognition of the need for rapid outbreak response. This shift has enabled faster market entry for assays targeting NS1 antigens and IgM antibodies, fostering a more competitive environment. Parallel to regulatory evolution, digital health platforms have emerged as pivotal enablers, linking test devices with cloud-based analytics to support remote interpretation, trend analysis, and integration with electronic health records.

Collectively, these developments are redefining patient pathways and public health strategies. Clinics and research institutes can now leverage real-time data streams to anticipate case surges, while hospitals and diagnostic laboratories benefit from consolidated workflows that reduce turnaround times and operational costs. As the dengue testing ecosystem continues to adapt, stakeholders that embrace these transformative shifts will be best positioned to deliver timely, accurate, and cost-effective solutions.

Assessing the Ripple Effects of 2025 U.S. Tariffs on Dengue Testing

In 2025, the imposition of new U.S. tariffs on imported diagnostic reagents, test kits, and instrumentation has introduced additional cost pressures across the dengue testing value chain. Suppliers reliant on overseas manufacturing have faced higher input expenses, compelling some to pass costs to laboratories and end users. As a result, procurement budgets at hospitals and diagnostic centers have tightened, prompting a reevaluation of supplier partnerships and sourcing strategies.

This tariff regime has also catalyzed a strategic push toward localized production. Instrument manufacturers and consumables providers have accelerated investments in domestic facilities to mitigate exposure to import duties. While this shift promises long-term supply chain resilience and reduced transportation lead times, it entails significant capital expenditure and potential delays in capacity ramp-up.

Laboratories and clinics have responded by diversifying their portfolios, incorporating a blend of locally produced assays alongside established imports to balance cost and performance. Research institutes collaborating with instrument vendors have underscored the importance of technology transfer agreements and joint development initiatives to foster innovation and secure stable supply channels. Given these dynamics, organizations that proactively adapt their sourcing frameworks and build strategic alliances will be better insulated from ongoing tariff fluctuations and able to maintain continuity in dengue diagnostic testing.

Unveiling Segmentation Dynamics Driving the Market

A nuanced understanding of market segmentation provides clarity on where innovation and investment are most critical. In the realm of test types, antibody assays continue to dominate due to their ability to distinguish between IgG and IgM responses, while antigen testing leverages NS1 detection through both enzyme linked immunosorbent assays and rapid formats to identify early-stage infections. Molecular diagnostics, encompassing conventional polymerase chain reaction and real time polymerase chain reaction, remain indispensable for confirming active viral replication and supporting surveillance efforts.

Technological segmentation further illuminates competitive dynamics. Enzyme linked immunosorbent assays maintain a strong foothold in laboratory settings, while lateral flow immunoassays, including colloidal gold and fluorescent formats, empower point-of-care environments. Microarray platforms offer multiplexing advantages for research applications, and polymerase chain reaction technologies underpin both high-volume hospital laboratories and specialized research institutes through their conventional and real-time variants.

Diverse end users such as clinics, diagnostic laboratories, hospitals, and research institutes drive demand for customized solutions, each with distinct throughput requirements, staffing expertise, and infrastructure capabilities. Product portfolios, spanning instruments like thermal cyclers and readers to software solutions and test kits, must align with these operational realities. Distribution across central laboratory networks and point-of-care settings dictates different training, maintenance, and quality assurance protocols, while sample types-plasma, serum, and whole blood-inform assay sensitivity, collection logistics, and patient preferences. This granular view of segmentation lays the groundwork for targeted strategies that resonate with specific stakeholder needs.

Regional Nuances Steering Dengue Testing Adoption

Regional dynamics exert a powerful influence on the trajectory of dengue testing adoption and innovation. In the Americas, established public health infrastructures and significant investment in diagnostic laboratories have driven widespread deployment of both molecular and rapid antigen assays. Collaborative efforts between government agencies and private partners have bolstered surveillance networks, ensuring that testing capacity scales with seasonal case fluctuations.

In the combined Europe, Middle East & Africa region, regulatory harmonization efforts and differential disease prevalence create a mosaic of opportunities and challenges. European centers of excellence prioritize high-sensitivity molecular testing, while resource-constrained markets in the Middle East and Africa are adopting cost-effective point-of-care solutions to expand reach. Partnerships with global health organizations have accelerated training programs and strengthened supply chains in underserved areas.

Asia-Pacific remains a hotspot for dengue research and testing innovation, driven by high case burdens and supportive regulatory frameworks that expedite assay approvals. Adoption of real-time polymerase chain reaction technologies and advanced immunoassays is widespread in urban centers, while rural and peri-urban clinics increasingly rely on rapid antigen tests. Local manufacturers are also scaling production to meet both domestic and export demand, underscoring the region’s dual role as a consumer and supplier in the dengue diagnostics ecosystem.

Competitive Landscape Advancing Diagnostics

Market leadership in dengue diagnostics is marked by companies that blend deep domain expertise with agile innovation strategies. Established global diagnostic firms continue to expand their assay portfolios, integrating next-generation molecular platforms with enhanced multiplexing capabilities and streamlined workflows. These players leverage extensive distribution networks and regulatory experience to accelerate market access in both developed and emerging markets.

At the same time, specialized biotechnology companies are carving out niches with point-of-care devices that combine rapid antigen detection with mobile connectivity for real-time data reporting. Strategic collaborations between instrument manufacturers and reagent suppliers have given rise to integrated solutions that bundle hardware, software, and consumables under unified service agreements, simplifying procurement and support for end users.

Research-driven startups are also making inroads by introducing novel assay chemistries and miniaturized testing devices tailored to low-resource settings. By focusing on cost optimization and ease of use, these entrants challenge traditional paradigms of centralized testing and catalyze broader adoption at the community level. Collectively, these competitive dynamics underscore a market in which innovation, strategic partnerships, and customer-centric models define the path to differentiation and growth.

Strategic Imperatives for Leaders to Capitalize on Trends

Industry leaders seeking to capitalize on burgeoning opportunities in dengue testing must adopt a multi-pronged strategy that aligns technological innovation with market realities. First, expanding point-of-care capabilities through investment in lateral flow immunoassays and portable molecular platforms will enable rapid case identification in decentralized settings. Complementary partnerships with software providers can unlock digital reporting functionalities, enhancing data visibility and enabling real-time surveillance.

Second, diversifying supply chains by forging partnerships with regional manufacturers will reduce exposure to tariff-induced cost volatility and strengthen local responsiveness. Joint ventures and technology transfer agreements can accelerate capacity building while ensuring adherence to quality standards.

Third, fostering collaborations with health authorities and research institutes will expedite validation studies and streamline regulatory pathways. Co-development initiatives can tailor assays to address regional serotype prevalence and emerging viral variants, ensuring that diagnostic solutions remain relevant and resilient.

By integrating these strategic imperatives-innovation in assay formats, supply chain resilience, and stakeholder collaboration-industry leaders can deliver scalable, cost-effective diagnostics that meet the evolving demands of healthcare systems worldwide.

Robust Research Framework Underpinning Our Analysis

This analysis rests on a robust research framework that combines comprehensive secondary data review with primary qualitative insights. Key peer-reviewed literature, regulatory filings, and industry white papers provided foundational context for market dynamics and technological trends. In parallel, in-depth interviews with diagnostic laboratory directors, assay developers, and public health officials enriched the study with firsthand perspectives on adoption barriers, operational challenges, and unmet needs.

Segmentation analysis drew on product catalogs, clinical guidelines, and laboratory protocols to accurately map test types, technology platforms, end user requirements, product portfolios, distribution channels, and sample handling practices. Regional insights were triangulated using trade publications, government reports, and expert commentary to capture nuanced variations across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Throughout the research process, methodological rigor was maintained through cross-validation of data sources and transparent documentation of assumptions. While the study does not rely on proprietary forecasts or proprietary surveys, it leverages credible public and expert inputs to deliver a clear and balanced view of the dengue testing landscape.

Synthesis of Insights Concluding Perspectives

The dengue testing landscape stands at an inflection point, shaped by technological breakthroughs, regulatory evolution, and shifting market forces. Molecular and immunoassay advancements have expanded diagnostic capabilities beyond traditional laboratory confines, while tariffs and supply chain dynamics are reshaping sourcing strategies. Segmentation insights reveal targeted areas for innovation, from antibody and antigen assays to point-of-care devices and high-throughput platforms. Regional nuances underscore the importance of tailored approaches that address local infrastructure, prevalence patterns, and regulatory requirements.

As diagnostic stakeholders chart their course, collaboration across industry, government, and research institutions will be critical to sustaining momentum. By aligning product development with end user needs, optimizing supply chains for resilience, and leveraging digital integration for enhanced data visibility, organizations can drive more effective case management and outbreak response. The strategic recommendations outlined here offer a roadmap to navigate complexity and deliver solutions that improve patient outcomes and public health resilience.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Antibody Test
      • Igg Antibody Test
      • Igm Antibody Test
    • Antigen Test
      • Ns1 Enzyme Linked Immunosorbent Assay
      • Ns1 Rapid Test
    • Molecular Test
      • Conventional Polymerase Chain Reaction
      • Real Time Polymerase Chain Reaction
  • Technology
    • Enzyme Linked Immunosorbent Assay
    • Lateral Flow Immunoassay
      • Colloidal Gold Assay
      • Fluorescent Immunoassay
    • Microarray Technology
    • Polymerase Chain Reaction
      • Conventional Polymerase Chain Reaction
      • Real Time Polymerase Chain Reaction
  • End User
    • Clinics
    • Diagnostic Laboratories
    • Hospitals
    • Research Institutes
  • Product Type
    • Instruments
      • Readers
      • Thermal Cyclers
    • Software Solutions
    • Test Kits
  • Setting
    • Central Laboratory
    • Point Of Care
  • Sample Type
    • Plasma
    • Serum
    • Whole Blood
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • bioM9rieux SA
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Meridian Bioscience, Inc.
  • Chembio Diagnostics, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Dengue Testing Market, by Test Type
8.1. Introduction
8.2. Antibody Test
8.2.1. Igg Antibody Test
8.2.2. Igm Antibody Test
8.3. Antigen Test
8.3.1. Ns1 Enzyme Linked Immunosorbent Assay
8.3.2. Ns1 Rapid Test
8.4. Molecular Test
8.4.1. Conventional Polymerase Chain Reaction
8.4.2. Real Time Polymerase Chain Reaction

9. Dengue Testing Market, by Technology
9.1. Introduction
9.2. Enzyme Linked Immunosorbent Assay
9.3. Lateral Flow Immunoassay
9.3.1. Colloidal Gold Assay
9.3.2. Fluorescent Immunoassay
9.4. Microarray Technology
9.5. Polymerase Chain Reaction
9.5.1. Conventional Polymerase Chain Reaction
9.5.2. Real Time Polymerase Chain Reaction

10. Dengue Testing Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Diagnostic Laboratories
10.4. Hospitals
10.5. Research Institutes

11. Dengue Testing Market, by Product Type
11.1. Introduction
11.2. Instruments
11.2.1. Readers
11.2.2. Thermal Cyclers
11.3. Software Solutions
11.4. Test Kits

12. Dengue Testing Market, by Setting
12.1. Introduction
12.2. Central Laboratory
12.3. Point Of Care

13. Dengue Testing Market, by Sample Type
13.1. Introduction
13.2. Plasma
13.3. Serum
13.4. Whole Blood

14. Americas Dengue Testing Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina

15. Europe, Middle East & Africa Dengue Testing Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland

16. Asia-Pacific Dengue Testing Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan

17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. F. Hoffmann-La Roche Ltd
17.3.3. Thermo Fisher Scientific Inc.
17.3.4. Danaher Corporation
17.3.5. bioM9rieux SA
17.3.6. QIAGEN N.V.
17.3.7. Bio-Rad Laboratories, Inc.
17.3.8. Siemens Healthineers AG
17.3.9. Meridian Bioscience, Inc.
17.3.10. Chembio Diagnostics, Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

List of Figures
FIGURE 1. DENGUE TESTING MARKET MULTI-CURRENCY
FIGURE 2. DENGUE TESTING MARKET MULTI-LANGUAGE
FIGURE 3. DENGUE TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DENGUE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DENGUE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DENGUE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DENGUE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DENGUE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

List of Tables
TABLE 1. DENGUE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DENGUE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DENGUE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DENGUE TESTING MARKET SIZE, BY IGG ANTIBODY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DENGUE TESTING MARKET SIZE, BY IGM ANTIBODY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DENGUE TESTING MARKET SIZE, BY NS1 RAPID TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DENGUE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DENGUE TESTING MARKET SIZE, BY COLLOIDAL GOLD ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DENGUE TESTING MARKET SIZE, BY FLUORESCENT IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DENGUE TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DENGUE TESTING MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DENGUE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DENGUE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DENGUE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DENGUE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DENGUE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DENGUE TESTING MARKET SIZE, BY READERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DENGUE TESTING MARKET SIZE, BY THERMAL CYCLERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DENGUE TESTING MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DENGUE TESTING MARKET SIZE, BY TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DENGUE TESTING MARKET SIZE, BY CENTRAL LABORATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DENGUE TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DENGUE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DENGUE TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DENGUE TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES DENGUE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. CANADA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 76. CANADA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 77. CANADA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 78. CANADA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 79. CANADA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. CANADA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 81. CANADA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 82. CANADA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. CANADA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. CANADA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 85. CANADA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 86. CANADA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 89. MEXICO DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 90. MEXICO DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 91. MEXICO DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 92. MEXICO DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 93. MEXICO DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 98. MEXICO DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA DENGUE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 148. GERMANY DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 149. GERMANY DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 150. GERMANY DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 151. GERMANY DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 152. GERMANY DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 153. GERMANY DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 154. GERMANY DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. GERMANY DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. GERMANY DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 158. GERMANY DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 159. GERMANY DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 160. FRANCE DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 161. FRANCE DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 162. FRANCE DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 163. FRANCE DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 164. FRANCE DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. FRANCE DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 166. FRANCE DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 167. FRANCE DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. FRANCE DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. FRANCE DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 170. FRANCE DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 171. FRANCE DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 184. ITALY DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 185. ITALY DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 186. ITALY DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 187. ITALY DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 188. ITALY DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. ITALY DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 190. ITALY DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 191. ITALY DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. ITALY DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. ITALY DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 194. ITALY DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 195. ITALY DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 196. SPAIN DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 197. SPAIN DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 198. SPAIN DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 199. SPAIN DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 200. SPAIN DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. SPAIN DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 202. SPAIN DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 203. SPAIN DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. SPAIN DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. SPAIN DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 206. SPAIN DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 207. SPAIN DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 244. DENMARK DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 245. DENMARK DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 246. DENMARK DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 247. DENMARK DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 248. DENMARK DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. DENMARK DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 250. DENMARK DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 251. DENMARK DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. DENMARK DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. DENMARK DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 255. DENMARK DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 268. QATAR DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 269. QATAR DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 270. QATAR DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 271. QATAR DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 272. QATAR DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 273. QATAR DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 274. QATAR DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 275. QATAR DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. QATAR DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. QATAR DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 278. QATAR DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 279. QATAR DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 280. FINLAND DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 281. FINLAND DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 282. FINLAND DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 283. FINLAND DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 284. FINLAND DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 285. FINLAND DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 286. FINLAND DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 287. FINLAND DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. FINLAND DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. FINLAND DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 290. FINLAND DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 291. FINLAND DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 316. EGYPT DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 317. EGYPT DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 318. EGYPT DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 319. EGYPT DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 320. EGYPT DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 321. EGYPT DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 322. EGYPT DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 323. EGYPT DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. EGYPT DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 325. EGYPT DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 326. EGYPT DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 327. EGYPT DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 328. TURKEY DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 329. TURKEY DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 330. TURKEY DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 331. TURKEY DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 332. TURKEY DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 333. TURKEY DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 334. TURKEY DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 335. TURKEY DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 336. TURKEY DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 337. TURKEY DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 338. TURKEY DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 339. TURKEY DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 340. ISRAEL DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 341. ISRAEL DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 342. ISRAEL DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 343. ISRAEL DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 344. ISRAEL DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 345. ISRAEL DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 346. ISRAEL DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 347. ISRAEL DENGUE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 348. ISRAEL DENGUE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 349. ISRAEL DENGUE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 350. ISRAEL DENGUE TESTING MARKET SIZE, BY SETTING, 2018-2030 (USD MILLION)
TABLE 351. ISRAEL DENGUE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 352. NORWAY DENGUE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 353. NORWAY DENGUE TESTING MARKET SIZE, BY ANTIBODY TEST, 2018-2030 (USD MILLION)
TABLE 354. NORWAY DENGUE TESTING MARKET SIZE, BY ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 355. NORWAY DENGUE TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2030 (USD MILLION)
TABLE 356. NORWAY DENGUE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 357. NORWAY DENGUE TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 358. NORWAY DENGUE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2030 (USD MILLION)
TABLE 359. NORWAY DENGUE TESTING M

Companies Mentioned

The companies profiled in this Dengue Testing market report include:
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • bioM9rieux SA
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Meridian Bioscience, Inc.
  • Chembio Diagnostics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 558.61 Million
Forecasted Market Value ( USD ) by 2030 $ 738.13 Million
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dengue Fever Diagnosis & Treatment Market by Product Type, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Dengue Fever Diagnosis & Treatment Market by Product Type, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Dengue Testing - Global Strategic Business Report - Product Image

Dengue Testing - Global Strategic Business Report

  • Report
  • 158 Pages
  • Global
From
Dengue Testing Market Report by Test Type, End User, and Region 2025-2033 - Product Image

Dengue Testing Market Report by Test Type, End User, and Region 2025-2033

  • Report
  • 144 Pages
  • Global
From
Dengue Virus Diagnostic Test Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Dengue Virus Diagnostic Test Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 88 Pages
  • Global
From

About the Dengue Test Market

The Dengue Test market is a subset of the Diagnostics industry, which focuses on the detection and diagnosis of diseases. Dengue is a mosquito-borne viral infection that is endemic in tropical and subtropical regions. Diagnostic tests for dengue are used to detect the presence of the virus in a patient's blood sample. These tests are used to diagnose dengue fever, as well as to differentiate between the four serotypes of the virus. The Dengue Test market is driven by the increasing prevalence of dengue fever, as well as the growing demand for rapid and accurate diagnostic tests. The market is also driven by the increasing availability of diagnostic kits and the development of new technologies for the detection of dengue. Some of the major players in the Dengue Test market include Abbott Laboratories, Bio-Rad Laboratories, DiaSorin, F. Hoffmann-La Roche, and Siemens Healthineers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.